<DOC>
	<DOCNO>NCT00528996</DOCNO>
	<brief_summary>The primary objective study compare bronchodilator efficacy three dos ( 50 µg , 100 µg 200 µg ) BEA 2180 deliver Respimat® daily placebo tiotropium bromide deliver Respimat® patient COPD . Additional objective include compare effect dyspnea health status .</brief_summary>
	<brief_title>An Efficacy Safety Study Compare Three Doses BEA 2180 BR Tiotropium Placebo Respimat Inhaler .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . All patient must sign informed consent consistent ICHGCP guideline prior participation trial , include medication washout restriction . 2 . All patient must diagnosis chronic obstructive pulmonary disease ( P95 4381 ) must meet follow spirometric criterion : Patients must relatively stable , moderate severe airway obstruction FEV1 ( postbronchodilator , 30 minute post salbutamol/albuterol ) &lt; 80 % predict normal FEV1 le equal 70 % FVC PFTs Visit 1 ( screen ) . 3 . Male female patient 40 year age old . 4 . Patients must current exsmokers smoke history 10 pack year . Patients never smoke cigarette must exclude . 5 . Patients must able perform technically acceptable pulmonary function test electronic PEFR measurement , must able maintain record ( Patient Daily Diary ) study period require protocol . 6 . Patients must able inhale medication competent manner Respimat® inhaler ( Appendix I ) 1 . Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient ability participate study . 2 . Patients clinically relevant abnormal baseline haematology , blood chemistry urinalysis , abnormality defines significant disease define exclusion criterion No . 1 . 3 . Patients recent history ( one year less ) myocardial infarction . 4 . Patients unstable lifethreatening cardiac arrhythmia . 5 . Patients hospitalized heart failure within past 3 year . 6 . Patients malignancy patient undergone resection , radiation therapy chemotherapy within last five year . Patients treat basal cell carcinoma allow . 7 . Patients know symptomatic prostatic hyperplasia bladder neck obstruction define exclusion criterion No . 1 . 8 . Patients know narrowangle glaucoma . 9 . Patients asthma history asthma . 10 . Patients history lifethreatening pulmonary obstruction , history cystic fibrosis clinically evident bronchiectasis . 11 . Patients know active tuberculosis . 12 . Patients history and/or active significant alcohol drug abuse . See exclusion criterion No . 1 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>